Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MACOV

Financiado

Macrophage-based immunotherapy of platinum-resistant ovarian cancer

Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer. About 300,000 women are diagnosed with ovarian cancer each year and the number of deaths is estimated at 180,000 worldwide each year. Ovari... ver más

31/10/2025

CELLIS

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

CELLIS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCI... No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-10-27

HORIZON-EIC-2022-TRANSITIONOPEN-01: EIC Transition Open 2022 Expected Impact:At the end of the EIC Transition project, it should be ready for the next stage, whi...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CELLIS

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AGAINST Achieving the golden Grail in solid tumor treatment 150K€ Cerrado

RYC2021-034893-I Dissecting the role of melanoma plasticity in metastasis and... 236K€ Cerrado

RYC-2014-15422 Unravelling the mechanisms of melanoma initiation, metastasi... 309K€ Cerrado

PID2021-124010OB-I00 FARMACOS MULTI-DIANA EN LA INMUNOTERAPIA DEL CANCER: DESCUBR... 145K€ Cerrado

PTQ-17-09270 ANTIMO: DESARROLLO DE ANTICUERPOS BIESPECÍFICOS ANTI HER3 CO... 96K€ Cerrado

PLEC2021-007959 USO DE LA INHIBICIÓN DE MYC PARA SUPERAR LA RESISTENCIA A LA... 378K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2022-10-27
Fecha Fin: 2025-10-31

Líder del proyecto

CELLIS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCI... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Descripción del proyecto Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer. About 300,000 women are diagnosed with ovarian cancer each year and the number of deaths is estimated at 180,000 worldwide each year. Ovarian cancer metastasizes early in its development, often before it's diagnosed. Ovarian cancer treatment involves surgery with frontline platinum-based chemotherapy. As many as 15-30% of patients with ovarian cancer have primary platinum-resistant or refractory disease. The recurrence of ovarian cancer is now considered a sign of an incurable disease (it becomes platinum-resistant). The project MACOV aims to develop an innovative allogeneic, ready-to-use macrophage-based therapy for platinum-resistant ovarian cancer. This is a ground-breaking, first in class therapy that shows very high efficacy in multiple solid tumors of unmet medical need. These cells are equipped with targeted therapy drugs complexed with the carrier protein ensuring their stability in the carrier cell. The protein-drug complex is transferred specifically to cancer cells. The whole concept of this cell therapy is based on the groundbreaking scientific discoveries of MDC (Macrophage-Drug Conjugate). Two European Research Council (ERC) grants were received to study the molecular basis of the discovered mechanism - in 2016 and 2020. In 2018 this project was selected to be promoted as one of the 10 European projects during ERC 10th Anniversary. The MACOV project will generate of complete efficacy data package for the pre-clinical development of MDC-735 product, consisting of efficacy in multiple animal models for platinum-resistant ovarian cancer, PK, PD and toxicology study as well as consolidate IP and validate business case. The result of the project will be a validated cell therapy product for platinum-refractory ovarian cancer, tested for effectiveness and ready-to-use for the Phase I clinical trial.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores